Consort Medical

Leading pharmaceutical manufacturer, Aesica, has opened a new analytical chemistry laboratory and GMP suite to significantly extend and enhance its Formulation Development capability.

The new facilities at Aesica’s site in Nottingham include a dedicated analytical chemistry laboratory to test inhalation devices, which is vital, as inhalation dosage forms currently represent almost 40 per cent of Aesica’s Formulation Development business. There is also a new GMP manufacturing suite, which will almost double the production capacity of clinical trial materials across all dosage forms.

Following the expansion in the UK, Aesica also plans to extend its Formulation Development capabilities by launching a second site from within its Formulated Products plant in Zwickau, Germany. The site specialises in the production of tablets, capsules and pellet/beads and has a well-equipped development laboratory. As Aesica looks to expand its customer base in Germany, dedicated local Formulation Development expertise is crucial and the launch of the new site is set for January 2012.

Paul Titley, Managing Director, Formulation Development, Aesica says: “The opening of our new facilities represents a key milestone for the Formulation Development team in Nottingham as it is exactly five years to the day since I launched R5 Pharmaceuticals on October 3rd 2006 at CPhI in Paris. Since then we were acquired by Aesica in June 2010 and with the support of the Executive team have now come full circle and grown into a new, bigger space in order to meet growing market demand.

“The new laboratory and indeed the expansion of our service offering in Germany is strategically crucial for the continued growth and evolution of Aesica’s Formulation Development offering.. Creating a site within the existing plant in Zwickau will also have a significant impact upon business development as it is imperative that we can provide a local service to our German based clients and this expansion into Europe will provide the ideal platform for further growth into the US and Asia next year.”

Aesica is a leading full-service provider of development and manufacturing services for Formulated Products and Active Pharmaceutical Ingredients. The company develops long-term strategic partnerships with its clients, responds quickly and effectively to market demand and develops tailored solutions for specific requirements.